PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1877391
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1877391
Anticancer Drug Market, By Route of Administration, By Drug Class, By Indication, By Distribution Channels, By Dosage Form, By End-Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
Anticancer Drug Market size was valued at US$ 166,669.56 Million in 2024, expanding at a CAGR of 9.5% from 2025 to 2032.
Anticancer drugs, also known as antineoplastic drugs, are medications that prevent malignant or cancerous cells from growing and spreading. The market is primarily driven by rising global cancer prevalence and increased investments in oncology research, which will result in the development of targeted therapies and personalized medicine. However, the high cost of anticancer treatments and stringent regulatory approval processes limit access in low- and middle-income countries. Nevertheless, significant opportunities exist for the advancement of immunotherapies and precision oncology, which use genetic profiling to provide more effective and less toxic treatment options. Continuous innovation in biologics and combination therapies is expected to drive market growth in the coming years.
Anticancer Drug Market- Market Dynamics
Increasing Prevalence of Cancer to Augment Market Growth
The rising global cancer incidence is one of the primary drivers of the anticancer drug market's growth. Aging populations, changing lifestyles, environmental pollution, and genetic predispositions all contribute to an increase in cancer cases around the world. As the number of patients grows, so does the demand for effective and advanced treatment options such as targeted therapies, immunotherapies, and personalized medicines. This surge is encouraging pharmaceutical companies to increase their R&D investments and develop novel therapeutics to improve patient outcomes. For instance, the World Health Organization (WHO) predicts that the number of new cancer cases will rise from 18.1 million in 2018 to 29.4 million by 2040, highlighting the critical need for innovative anticancer drugs and supporting continued market growth during the forecast period.
Anticancer Drug Market- Segmentation Analysis:
The Global Anticancer Drug Market is segmented on the basis of Route of Administration, Drug Class, Indication, Distribution Channels, Dosage Form, End-Users, and Region.
In terms of Dosage Form, the Anticancer Drug Market is divided into Solid (Tablets, Capsules), Injectable (Prefilled Syringes, Others), Liquid, and Others. Among these, the injectable segment is a significant revenue generator, driven by the growing use of biologics and targeted therapies that require parenteral administration for improved efficacy and controlled release. In oncology, injectables are widely used because they allow for precise dosing, rapid systemic absorption, and improved treatment outcomes when administered under medical supervision. Moreover, the increasing availability of biosimilars and generic injectable formulations is broadening access and driving market expansion. For example, in September 2020, Mylan N.V. announced the U.S. launch of Fulvestrant Injection (250 mg/5 mL), a generic version of AstraZeneca's Faslodex used to treat certain types of advanced breast cancer in women, demonstrating ongoing innovation and market activity in this segment.
Based on drug class, targeted therapy is an important segment of the anticancer drug market due to its ability to selectively attack malignant cells while minimizing damage to healthy tissues, thereby improving treatment efficacy and lowering toxicity. This precision-based approach focuses directly on disease mechanisms while minimizing off-target effects, resulting in higher adoption than conventional chemotherapy. The growing portfolio of FDA-approved monoclonal antibodies, kinase inhibitors, and immune-modulating agents demonstrates significant progress in cancer research and development. Furthermore, the combination of genomic testing and companion diagnostics has increased treatment accuracy, allowing for more personalized and effective cancer care. The growing number of regulatory approvals for novel targeted therapies, combined with a strong pipeline of investigational drugs, is boosting this segment's market potential. For instance, in June 2023, the US FDA approved the combination of dabrafenib and trametinib for pediatric and adult patients with BRAF V600E-mutated cancers, highlighting the ongoing innovation and clinical progress that is driving growth in the targeted therapy segment.
Anticancer Drug Market- Geographical Insights
The Anticancer Drug Market exhibits notable regional diversity, shaped by differences in healthcare infrastructure, cancer prevalence, and access to advanced therapies. Asia-Pacific remains a key growth region for the market, accounting for roughly 20% of the global share. The rising incidence of cancer, increased healthcare expenditure, and expanded access to modern oncology treatments all contribute to growth in this region. Rapid urbanization, lifestyle changes, and an ageing population all contribute to the rise in disease prevalence. Countries such as China, India, and Japan are investing heavily in oncology research, clinical trials, and healthcare infrastructure to meet the rising demand for cancer care. Furthermore, increased patient awareness, supportive government initiatives, and improved reimbursement frameworks are easing the adoption of novel therapies such as targeted drugs, immunotherapies, and combination treatments.
China Anticancer Drug Market- Country Insights
China's large population, rising cancer prevalence, and expanding healthcare infrastructure make it a key driver of the Asia-Pacific anticancer drugs market. According to World Health Organization data, China is expected to see approximately 4.3 million new cancer cases in 2025, with lung, breast, and colorectal cancers being the most common. The government is making substantial investments in oncology research, clinical trials, and hospital networks. Increased awareness, access to innovative therapies such as targeted treatments and immunotherapies, and supportive reimbursement policies are hastening the adoption of advanced anti-cancer drugs, establishing China as a dominant and rapidly growing market in the region.
Anticancer Drug Market- Competitive Landscape:
Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, and Johnson & Johnson are among the anticancer drug market key players. These companies are fueling competition with advances in targeted therapies, immuno-oncology, and precision medicine. The increasing use of checkpoint inhibitors, CAR-T cell therapies, and antibody-drug conjugates (ADCs) is changing treatment paradigms and driving R&D investments. Strategic collaborations, mergers, and acquisitions are common as companies seek to strengthen their oncology pipelines and expand globally. In addition, the combination of AI-powered drug discovery platforms and biomarker-based patient selection is hastening innovation. To address the increasing global cancer burden, the competitive landscape is characterized by rapid technological evolution, clinical trial expansion, and a focus on personalized, cost-effective cancer therapies.
Recent Developments:
In October 2025, AstraZeneca and Daiichi Sankyo announced that Datroway, a precision drug, improved survival rates in patients with advanced breast cancer in a late-stage trial. This development paves the way for more widespread approvals and possible market expansion.
In June 2025, Bristol Myers Squibb signed a $11 billion strategic collaboration agreement with BioNTech. The collaboration entails the co-development and commercialization of BioNTech's investigational bispecific antibody, BNT327, which targets a variety of solid tumor types. BioNTech received an initial payment of $1.5 billion, with non-contingent anniversary payments through 2028 and potential milestone payments of up to $7.6 billion. This collaboration represents a significant investment in the advancement of novel immuno-oncology therapies in the global anticancer drug market, intending to accelerate the development of this bispecific antibody in multiple indications.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTICANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Novartis
- Pfizer
- Merck & Co. (MSD)
- Bristol Myers Squibb (BMS)
- AstraZeneca
- Roche/Genentech
- Johnson & Johnson/Janssen
- Sanofi
- Eli Lilly & Co.
- Takeda
- Amgen
- BeiGene
- Regeneron
- Bluebird Bio
- Seagen
- Moderna
- Genmab
- Incyte
- Exelixis
- Hutchmed / Chi-Med
- Others
GLOBAL ANTICANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intravenous (IV)
- Subcutaneous
- Oral
- Topical / Localized
GLOBAL ANTICANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Chemotherapy
- Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
- Monoclonal Antibodies / Biologics
- Hormone Therapy
- Targeted Therapy
- Others (Oncolytic viruses, combination therapies, adjuncts)
GLOBAL ANTICANCER DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Blood Cancer
- Gynaecologic Cancer
- Others
GLOBAL ANTICANCER DRUG MARKET, BY DISTRIBUTION CHANNELS- MARKET ANALYSIS, 2019 - 2032
- Online Pharmacy
- Hospital Pharmacy
- Retail Pharmacy
GLOBAL ANTICANCER DRUG MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032
- Solid (Tablets, Capsule)
- Injectable (Prefilled Syringes, Others)
- Liquid
- Others
GLOBAL ANTICANCER DRUG MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032
- Specialty Clinics
- Hospitals
- Homecare
- Others
GLOBAL ANTICANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Anticancer Drug Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Anticancer Drug Market Snippet by Route of Administration
- 2.1.2. Anticancer Drug Market Snippet by Drug Class
- 2.1.3. Anticancer Drug Market Snippet by Indication
- 2.1.4. Anticancer Drug Market Snippet by Distribution Channels
- 2.1.5. Anticancer Drug Market Snippet by Dosage Form
- 2.1.6. Anticancer Drug Market Snippet by End-Users
- 2.1.7. Anticancer Drug Market Snippet by Country
- 2.1.8. Anticancer Drug Market Snippet by Region
- 2.2. Competitive Insights
3. Anticancer Drug Key Market Trends
- 3.1. Anticancer Drug Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Anticancer Drug Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Anticancer Drug Market Opportunities
- 3.4. Anticancer Drug Market Future Trends
4. Anticancer Drug Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Anticancer Drug Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Anticancer Drug Market Landscape
- 6.1. Anticancer Drug Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Anticancer Drug Market - By Route of Administration
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 7.1.2. Intravenous (IV)
- 7.1.3. Subcutaneous
- 7.1.4. Oral
- 7.1.5. Topical / Localized
8. Anticancer Drug Market - By Drug Class
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 8.1.2. Chemotherapy
- 8.1.3. Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
- 8.1.4. Monoclonal Antibodies / Biologics
- 8.1.5. Hormone Therapy
- 8.1.6. Targeted Therapy
- 8.1.7. Others (Oncolytic viruses, combination therapies, adjuncts)
9. Anticancer Drug Market - By Indication
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 9.1.2. Breast Cancer
- 9.1.3. Lung Cancer
- 9.1.4. Prostate Cancer
- 9.1.5. Gastrointestinal Cancer
- 9.1.6. Blood Cancer
- 9.1.7. Gynaecologic Cancer
- 9.1.8. Others
10. Anticancer Drug Market - By Distribution Channels
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Distribution Channels, 2024 & 2032 (%)
- 10.1.2. Online Pharmacy
- 10.1.3. Hospital Pharmacy
- 10.1.4. Retail Pharmacy
11. Anticancer Drug Market - By Dosage Form
- 11.1. Overview
- 11.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
- 11.1.2. Solid (Tablets, Capsule)
- 11.1.3. Injectable (Prefilled Syringes, Others)
- 11.1.4. Liquid
- 11.1.5. Others
12. Anticancer Drug Market - By End-Users
- 12.1. Overview
- 12.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
- 12.1.2. Specialty Clinics
- 12.1.3. Hospitals
- 12.1.4. Homecare
- 12.1.5. Others
13. Anticancer Drug Market- By Geography
- 13.1. Introduction
- 13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 13.2. North America
- 13.2.1. Overview
- 13.2.2. Anticancer Drug Key Manufacturers in North America
- 13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.2.7. North America Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.2.8. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.2.9. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.2.10. U.S.
- 13.2.10.1. Overview
- 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.2.10.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.2.10.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.2.10.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.2.10.6. U.S. Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.2.10.7. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.2.10.8. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.2.11. Canada
- 13.2.11.1. Overview
- 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.2.11.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.2.11.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.2.11.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.2.11.6. Canada Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.2.11.7. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.2.11.8. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3. Europe
- 13.3.1. Overview
- 13.3.2. Anticancer Drug Key Manufacturers in Europe
- 13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.7. Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.8. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.9. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.10. Germany
- 13.3.10.1. Overview
- 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.10.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.10.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.10.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.10.6. Germany Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.10.7. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.10.8. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.11. UK
- 13.3.11.1. Overview
- 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.11.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.11.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.11.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.11.6. UK Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.11.7. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.11.8. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.12. France
- 13.3.12.1. Overview
- 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.12.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.12.6. France Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.12.7. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.12.8. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.13. Italy
- 13.3.13.1. Overview
- 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.13.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.13.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.13.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.13.6. Italy Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.13.7. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.13.8. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.14. Spain
- 13.3.14.1. Overview
- 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.14.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.14.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.14.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.14.6. Spain Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.14.7. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.14.8. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.15. The Netherlands
- 13.3.15.1. Overview
- 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.15.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.15.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.15.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.15.6. The Netherlands Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.15.7. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.15.8. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.16. Sweden
- 13.3.16.1. Overview
- 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.16.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.16.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.16.6. Sweden Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.16.7. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.16.8. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.17. Russia
- 13.3.17.1. Overview
- 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.17.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.17.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.17.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.17.6. Russia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.17.7. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.17.8. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.18. Poland
- 13.3.18.1. Overview
- 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.18.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.18.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.18.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.18.6. Poland Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.18.7. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.18.8. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.3.19. Rest of Europe
- 13.3.19.1. Overview
- 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.3.19.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.19.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.3.19.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.3.19.6. Rest of the Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.3.19.7. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.3.19.8. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4. Asia Pacific (APAC)
- 13.4.1. Overview
- 13.4.2. Anticancer Drug Key Manufacturers in Asia Pacific
- 13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.7. APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.8. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.9. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.10. China
- 13.4.10.1. Overview
- 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.10.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.10.6. China Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.10.7. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.10.8. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.11. India
- 13.4.11.1. Overview
- 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.11.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.11.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.11.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.11.6. India Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.11.7. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.11.8. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.12. Japan
- 13.4.12.1. Overview
- 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.12.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.12.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.12.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.12.6. Japan Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.12.7. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.12.8. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.13. South Korea
- 13.4.13.1. Overview
- 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.13.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.13.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.13.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.13.6. South Korea Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.13.7. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.13.8. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.14. Australia
- 13.4.14.1. Overview
- 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.14.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.14.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.14.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.14.6. Australia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.14.7. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.14.8. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.15. Indonesia
- 13.4.15.1. Overview
- 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.15.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.15.6. Indonesia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.15.7. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.15.8. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.16. Thailand
- 13.4.16.1. Overview
- 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.16.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.16.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.16.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.16.6. Thailand Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.16.7. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.16.8. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.17. Philippines
- 13.4.17.1. Overview
- 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.17.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.17.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.17.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.17.6. Philippines Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.17.7. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.17.8. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.4.18. Rest of APAC
- 13.4.18.1. Overview
- 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.4.18.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.4.18.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.4.18.7. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.4.18.8. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5. Latin America (LATAM)
- 13.5.1. Overview
- 13.5.2. Anticancer Drug Key Manufacturers in Latin America
- 13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.5.7. LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.5.8. LATAM Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.5.9. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.10. Brazil
- 13.5.10.1. Overview
- 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.5.10.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.10.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.5.10.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.5.10.6. Brazil Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.5.10.7. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.5.10.8. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.11. Mexico
- 13.5.11.1. Overview
- 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.5.11.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.11.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.5.11.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.5.11.6. Mexico Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.5.11.7. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.5.11.8. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.12. Argentina
- 13.5.12.1. Overview
- 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.5.12.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.12.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.5.12.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.5.12.6. Argentina Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.5.12.7. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.5.12.8. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.13. Colombia
- 13.5.13.1. Overview
- 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.5.13.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.13.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.5.13.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.5.13.6. Colombia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.5.13.7. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.5.13.8. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.5.14. Rest of LATAM
- 13.5.14.1. Overview
- 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.5.14.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.14.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.5.14.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.5.14.6. Rest of LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.5.14.7. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.5.14.8. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6. Middle East and Africa
- 13.6.1. Overview
- 13.6.2. Anticancer Drug Key Manufacturers in Middle East and Africa
- 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.8. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.9. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.10. Saudi Arabia
- 13.6.10.1. Overview
- 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.6.10.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.10.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.10.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.10.6. Saudi Arabia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.10.7. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.10.8. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.11. United Arab Emirates
- 13.6.11.1. Overview
- 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.6.11.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.11.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.11.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.11.6. United Arab Emirates Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.11.7. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.11.8. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.12. Israel
- 13.6.12.1. Overview
- 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.6.12.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.12.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.12.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.12.6. Israel Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.12.7. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.12.8. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.13. Turkey
- 13.6.13.1. Overview
- 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.6.13.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.13.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.13.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.13.6. Turkey Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.13.7. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.13.8. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.14. Algeria
- 13.6.14.1. Overview
- 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.6.14.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.14.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.14.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.14.6. Algeria Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.14.7. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.14.8. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.15. Egypt
- 13.6.15.1. Overview
- 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.6.15.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.15.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.15.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.15.6. Egypt Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.15.7. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.15.8. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 13.6.16. Rest of MEA
- 13.6.16.1. Overview
- 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 13.6.16.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 13.6.16.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 13.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
- 13.6.16.7. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 13.6.16.8. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
14. Key Vendor Analysis- Anticancer Drug Industry
- 14.1. Competitive Benchmarking
- 14.1.1. Competitive Dashboard
- 14.1.2. Competitive Positioning
- 14.2. Company Profiles
- 14.2.1. Novartis
- 14.2.2. Pfizer
- 14.2.3. Merck & Co. (MSD)
- 14.2.4. Bristol Myers Squibb (BMS)
- 14.2.5. AstraZeneca
- 14.2.6. Roche/Genentech
- 14.2.7. Johnson & Johnson/Janssen
- 14.2.8. Sanofi
- 14.2.9. Eli Lilly & Co.
- 14.2.10. Takeda
- 14.2.11. Amgen
- 14.2.12. BeiGene
- 14.2.13. Regeneron
- 14.2.14. Bluebird Bio
- 14.2.15. Seagen
- 14.2.16. Moderna
- 14.2.17. Genmab
- 14.2.18. Incyte
- 14.2.19. Exelixis
- 14.2.20. Hutchmed / Chi-Med
- 14.2.21. Others
15. 360 Degree Analyst View
16. Appendix
- 16.1. Research Methodology
- 16.2. References
- 16.3. Abbreviations
- 16.4. Disclaimer
- 16.5. Contact Us
